Bal Pharma share news, announcements and annual reports
NSE: BALPHARMABSE: 524824Pharmaceuticals & BiotechnologySmall Cap
Bal Pharma Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 1995 on BSE, May 2006 on NSE
Last close ₹81.85down ₹2.76 (3.26%)BSE ₹81.20
Share price at the NSE close on 30 Oct 2026. Previous close ₹84.61.
30 Oct: open ₹84.05, high ₹84.05, low ₹81.21
52-week range of traded prices to 30 Oct 2026
₹60.00Low, 30 Mar 2026₹124.60High, 10 Sep 2026
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹130 Cr2,779th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 18.08
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.58
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 1.47%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 9.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 9.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 1.94
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 6,401
Bal Pharma board meetings
132 filed, newest first. Page 2 of 3.
Jul 2020
29 Jul · Board meeting
Jun 2020
12 Jun · Board meeting
May 2020
23 May · Board meeting
Feb 2020
12 Feb · Board meeting
Jan 2020
22 Jan · Board meeting
Nov 2019
15 Nov · Board meeting
14 Nov · Board meeting
Oct 2019
23 Oct · Board meeting
Aug 2019
13 Aug · Board meeting
Jul 2019
May 2019
30 May · Board meeting
Apr 2019
Feb 2019
13 Feb · Board meeting
Jan 2019
14 Jan · Board meeting
Nov 2018
14 Nov · Board meeting
Oct 2018
Aug 2018
10 Aug · Board meeting
Jul 2018
May 2018
Feb 2018
14 Feb · Board meeting
Jan 2018
Nov 2017
Sep 2017
12 Sep · Board meeting
Aug 2017
Jul 2017
May 2017
30 May · Board meeting
Jan 2017
Oct 2016
Jul 2016
May 2016
Apr 2016
Jan 2016
Oct 2015
Aug 2015
Jul 2015
May 2015
Feb 2015
Oct 2014
31 Oct · Board meeting
Inter alia will be taking on record and approve the Un-Audited Financial Results of the Company for the quarter and half year ended September 30, 2014.16 Oct · Board meeting
Board of Directors inter alia will consider issue and allotment of warrants to the investors on preferential basis.
Jul 2014
30 Jul · Board meeting
Inter alia will be taking on record and approve the Un-Audited financial results of the Company for the quarter ended June 30, 2014.
May 2014
9 May · Board meeting
Inter alia will be transacting the following business, 1. Consideration of the Audited Financial Results of the Company for the IVth quarter and financial year ended 31.03.2014. 2. Appropriation of profits including recommendation of Dividend, if any. 3. Consideration of various subjects relating to Annual General Meeting. 4. Book closure and Convening of A.G.M . 5. Any other business with the permission of the Chairman.
Apr 2014
Feb 2014
17 Feb · Board meeting
Board of Directors of the Company at its meeting held on February 12, 2014 has transacted the following business:(1) After having received the full consideration amount of Rs. 21/- per equity share, the Board has made the allotment of 5,37,764 equity shares of Rs. 10 each to Anita Siroya, on preferential basis. With this allotment, the paid up capital of the Company is enhanced to 1,11,11,388 equity shares of Rs. 10 each.
Jan 2014
Oct 2013
30 Oct · Board meeting
Board of Directors inter alia will be taking on record and approve the Un-Audited Financial Results of the Company for the quarter and half year ended September 30, 2013.
Jul 2013
22 Jul · Board meeting
Inter-alia, to take on record and approve the Un-Audited financial results of the Company for the quarter ended June 30, 2013.
May 2013
8 May · Board meeting
Inter alia, will be transacting the following: (1) To consider and approve the Audited Financial Results of the Company for the financial year ended March 31, 2013 (2) Recommendation of Dividend, if any (3) Approve the audited accounts of the Company for the FY ended March 31, 2013 along with the notice of A.G.M., Director s Report and Corporate Governance Report (4) To decide on the book closure and A G M date.
Jan 2013